GeneDx appoints Thomas Fuchs, SVP & Chief AI Officer at Lilly, as Class I director

GeneDx Holdings Corp.

Thomas Fuchs appointed to board effective September 17, 2025; board expands from 7 to 8 members.
Dr. Fuchs serves as SVP and Chief AI Officer at Eli Lilly, leading AI for drug discovery and clinical trials.
Initial RSU grant of $420,000 vesting over three years under non-employee director compensation policy.
Dr. Fuchs holds a doctorate in machine learning from ETH Zurich and founded Paige AI.
No transactions requiring disclosure under Item 404(a) and no arrangements with any person.

item 5.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.